Kicking off this discussion thread for ongoing community input on GH peptide research questions. The compounds in this category have been studied for longer than the GLP-1 class, but the protocol design space is wider — multiple compounds, multiple combinations, multiple dose patterns, and the timing-around-food-and-sleep variable that significantly affects outcomes. Plenty of room for productive Q&A. Reply with your own questions or respond to anyone else's.
Specific questions or experiences worth sharing.
Combination protocol experiences. If a research protocol used CJC-1295 + ipamorelin (or another GHRH + ghrelin mimetic combination), what dosing pattern was used? Two daily injections, three daily injections, pre-bed only? What did the timing relative to food and sleep look like? How did the protocol design choices compare to the published research literature?
Blood work patterns and timing. IGF-1 is the standard biomarker for GH peptide research. If IGF-1 was tracked, what was the baseline, what was the trajectory over the protocol, and when in relation to dosing was the draw timed? IGF-1 has a roughly 24-hour half-life so timing matters less than for some markers, but pre-protocol baseline and several-week intervals are the typical pattern. What did the numbers look like? Other blood work to consider: fasting glucose and insulin (some GH peptides can affect insulin sensitivity), prolactin and cortisol (relevant for GHRP-2, GHRP-6, hexarelin), and lipid panel.
MK-677 versus injectable comparison experiences. MK-677 is the only orally bioavailable secretagogue in this category and produces a fundamentally different pharmacological profile. If a protocol compared MK-677 to injectable secretagogues (either sequentially or in different research arms), what differences were observed? Water retention, hunger increase, sleep effects, IGF-1 trajectory? The 24-hour half-life and sustained elevation pattern produces effects that pulsatile injectables do not.
Sleep architecture changes. GH peptides frequently produce noticeable sleep changes in research subjects — typically deeper sleep, more vivid dreaming, sometimes increased total sleep time. If sleep was tracked objectively (Whoop, Oura, polysomnography in any setting), what did the deep sleep percentages look like before and during the protocol?
Side effect timing and resolution. Injection-site reactions, flushing, lightheadedness, increased hunger (with GHRP-6 or MK-677), and water retention are documented side effects in the research literature. If any of these appeared in a protocol, when did they show up, how severe were they, and did they resolve with continued exposure?
A note on framing.
This category attracts a wider range of researchers than the GLP-1 class — performance-oriented research, recovery-focused research, age-related GH decline research, and quality-of-life research all share these compounds. The community is more diverse than it appears at first. Please keep responses research-framed and try to specify what research context you are operating in — protocol design choices that make sense in a recovery research context may not transfer to a body-recomposition research context.
If you have questions but do not want to post them publicly, DMs are open. The thread is the right place for shareable Q&A but private messages work for vendor-specific questions or protocol-specific guidance.
